Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Myeloid 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Nasopharyngeal Carcinoma 71Nasopharyngeal Neoplasms 25Head and Neck Neoplasms 25Squamous Cell Carcinoma of Head and Neck 18Neoplasm Metastasis 14Carcinoma, Non-Small-Cell Lung 11Recurrence 9Salivary Gland Neoplasms 7Ovarian Neoplasms 7Stomach Neoplasms 6Pancreatic Neoplasms 6Small Cell Lung Carcinoma 5Prostatic Neoplasms 5Neoplasms 5Melanoma 5Colorectal Neoplasms 5Breast Neoplasms 5Triple Negative Breast Neoplasms 4Sarcoma 4Lung Neoplasms 4Esophageal Neoplasms 4Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Laryngeal Diseases 3Epstein-Barr Virus Infections 3Colonic Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Osteosarcoma 2Oropharyngeal Neoplasms 2Mouth Neoplasms 2

Interventions

Panitumumab 1PLX8394 1IFL protocol 1Gemcitabine 1Cetuximab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytosis × Gemcitabine × Head & Neck × Clear all
NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡